Acute Leukemia CPG Mini Module - Antibody-Drug Conjugates for Treatment of Acute Leukemia
The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.
A case presentation of a patient with acute myeloid leukemia is the starting point for a discussion of antibody-drug conjugates for treating acute leukemia. Presenter Steven D. Gore, MD - National Cancer Institute, Maryland, describes the clinical data that lead to the FDA approval of gemtuzumab for treating AML. Additional considerations including potential toxicities and adverse events are also discussed.
Run time: 14 minutes 15 seconds
Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021).
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.